Drug Trials Genetics Life Science 
XTalks
SEPTEMBER 11, 2020
A study published in JAMA Oncology found that in cancer drug trials conducted between 2008 and 2018, nearly two-thirds of participants were non-Hispanic whites. When trial populations don’t match the broader patient base, the treatments they produce aren’t as effective. Nearly all diseases have a genetic component.
XTalks
MAY 16, 2023
The exact cause of pulmonary fibrosis is often unknown, and in such cases, it is referred to as idiopathic pulmonary fibrosis (IPF); however, certain factors can contribute to the development of pulmonary fibrosis, including environmental and occupational exposures, certain medications, autoimmune diseases and genetic predisposition.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
SEPTEMBER 13, 2024
Generalizability: Determining if results from a diverse participant group can be applied more broadly across various populations outside the trial. Scientific Validity: Ensuring that diverse genetic backgrounds are considered, which can influence how patients metabolize drugs and respond to therapies.
XTalks
FEBRUARY 25, 2022
Despite these statistics, in the US, Black people only constitute five percent of all clinical trial participants. The overwhelming majority of trial participants nationwide are white. However, the links between race-based genetics and disease are not quite clear. Personalized Medicine.
Expert insights. Personalized for you.
98 
Let's personalize your content